Shares of Australian biotech Mesoblast (ASX: MSB) plummeted after it revealed that, the US Food and Drug Administration had issued a Complete Response Letter (CRL) to its Biologics License Application (BLA) for Ryoncil (remestemcel-L) for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD).
Mesoblast's shares, which went into a trading halt last Thursday in anticipation of the regulatory ruling, opened down 44% at A$2.87 on the back of the news Friday. The stock reversed some of the loss, closing up 11.6% to A$3.56 today.
While the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9:1 that the available data support the efficacy of remestemcel-L in pediatric patients with SR-aGVHD, the FDA recommended that Mesoblast conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD. As there are currently no approved treatments for this life-threatening condition in children under 12, Mesoblast will urgently request a Type A meeting with the FDA, expected within 30 days, to discuss a potential accelerated approval with a post-approval condition for an additional study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze